Skip to main content Skip to section navigation Skip to footer
Rezolute, Inc. IR Overview
  • About
    • Our Mission
    • Leadership
    • Board of Directors
  • Our Science
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • Patient Stories
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us

News

Investors

Investors

  • Overview
  • Corporate Presentation
  • Patient Stories
  • News
  • Events
  • Stock Quote and Chart
  • Historical Data
  • Analyst Coverage
  • SEC Filings
  • Governance
    • Governance Documents
  • Info
Mar 22, 2017 8:00 am EDT
AntriaBio Appoints Two Pharmaceutical Executives to its Board of Directors
Dec 15, 2016 5:15 pm EST
AntriaBio Announces Offer to Amend Warrants to Purchase Shares of Common Stock
Sep 22, 2016 8:00 am EDT
AntriaBio Announces Formation of Subsidiary and Plan to Raise Capital in South Korea
Jun 29, 2016 8:00 am EDT
AntriaBio Announces $12 Million Private Placement
Jun 22, 2016 8:00 am EDT
AntriaBio Announces Preclinical Proof of Concept for Once-Weekly Basal Insulin AB101 in Diabetic Miniature Swine
Jan 6, 2016 8:30 am EST
AntriaBio Announces Appointment of Michael Deperro as Vice President of Operations
Dec 10, 2015 12:50 pm EST
AntriaBio Announces First Close of Private Placement Transaction
Nov 17, 2015 8:30 am EST
AntriaBio Receives Notice of Allowance on Patent Covering Microsphere Drug Delivery Platform
Sep 16, 2015 7:30 am EDT
AntriaBio Announces New Product Candidate, AB301, a Weekly GLP-1 Agonist and Basal Insulin Combination, for Type 2 Diabetes
Jun 29, 2015 8:00 am EDT
AntriaBio Appoints David F. Welch, Ph.D. to Its Board of Directors
  • Previous Pagearrow_back
  • Page 1
  • …
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • Page 11
  • Page 12
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Next Pagearrow_forward
rss_feed News RSS

Stay Connected

  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Visit us on LinkedIn Visit us on X Visit us on Facebook
rezolute logo

©2025 Rezolute, Inc.

Explore

  • About
  • Approach
  • Pipeline
  • Publications
  • For Patients
  • Join Us
  • Investors & Media
  • Contact Us

Contact

Corporate Headquarters

275 Shoreline Drive
Suite 500
Redwood City, CA 94065

+1 (650) 206-4507
info@rezolutebio.com

Investor Relations

Oregon Office
2783 NW Lolo Drive
Suite 150
Bend, OR 97703

Legal

  • Terms of Use
  • Privacy Policy
MENU
  • About
    • Leadership
    • Board of Directors
    • Scientific Advisory Board
  • Approach
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Pipeline
    • Overview
    • Congenital Hyperinsulinism
    • Tumor Hyperinsulinism
    • Additional Programs
  • Publications
    • Publications
    • Data Presentations
  • For Patients
  • Join Us
    • Values
    • Benefits
    • Open Positions
  • Investors & Media
    • Overview
    • Corporate Presentation
    • Patient Stories
    • News
    • Events
    • Stock Quote and Chart
    • Historical Data
    • Analyst Coverage
    • SEC Filings
    • Governance
    • Info
  • Contact Us